

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in understanding and managing... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-720/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-720" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in understanding and managing non-alcoholic fatty liver disease" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in understanding and managing non-alcoholic fatty liver disease.">
            <meta name="og:description" content="Read the latest article version by Somaya Albhaisi, Arun Sanyal, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="15697">
            <meta name="article-id" content="14421">
            <meta name="dc.title" content="Recent advances in understanding and managing non-alcoholic fatty liver disease">
            <meta name="dc.description" content="Non-alcoholic fatty liver disease is a leading cause of chronic liver disease that can lead to cirrhosis, hepatocellular cancer, and end-stage liver disease, and it is linked to elevated cardiovascular- and cancer-related morbidity and mortality. Insulin resistance related to metabolic syndrome is the main pathogenic trigger that, in association with adverse genetic, lifestyle, and other factors, precipitates the development of non-alcoholic fatty liver disease. Biochemical markers and radiological imaging, along with liver biopsy in selected cases, help in the disease&rsquo;s diagnosis and prognostication. Weight loss is the cornerstone treatment of non-alcoholic fatty liver disease; however, it is difficult to achieve and maintain, so pharmacotherapy was developed. The remarkable evolution in understanding disease pathogenesis has led to the development of new medical therapies and even the modification of currently available ones. This review summarizes recent advances in understanding the epidemiology, natural history, pathogenesis, diagnosis, and management of non-alcoholic fatty liver disease.">
            <meta name="dc.subject" content="Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, cirrhosis, fibrosis">
            <meta name="dc.creator" content="Albhaisi, Somaya">
            <meta name="dc.creator" content="Sanyal, Arun">
            <meta name="dc.date" content="2018/06/11">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.14421.1">
            <meta name="dc.source" content="F1000Research 2018 7:720">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Nonalcoholic fatty liver disease">
            <meta name="prism.keyword" content="Nonalcoholic steatohepatitis">
            <meta name="prism.keyword" content="cirrhosis">
            <meta name="prism.keyword" content="fibrosis">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/06/11">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="720">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.14421.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-720">
            <meta name="citation_title" content="Recent advances in understanding and managing non-alcoholic fatty liver disease">
            <meta name="citation_abstract" content="Non-alcoholic fatty liver disease is a leading cause of chronic liver disease that can lead to cirrhosis, hepatocellular cancer, and end-stage liver disease, and it is linked to elevated cardiovascular- and cancer-related morbidity and mortality. Insulin resistance related to metabolic syndrome is the main pathogenic trigger that, in association with adverse genetic, lifestyle, and other factors, precipitates the development of non-alcoholic fatty liver disease. Biochemical markers and radiological imaging, along with liver biopsy in selected cases, help in the disease&rsquo;s diagnosis and prognostication. Weight loss is the cornerstone treatment of non-alcoholic fatty liver disease; however, it is difficult to achieve and maintain, so pharmacotherapy was developed. The remarkable evolution in understanding disease pathogenesis has led to the development of new medical therapies and even the modification of currently available ones. This review summarizes recent advances in understanding the epidemiology, natural history, pathogenesis, diagnosis, and management of non-alcoholic fatty liver disease.">
            <meta name="citation_description" content="Non-alcoholic fatty liver disease is a leading cause of chronic liver disease that can lead to cirrhosis, hepatocellular cancer, and end-stage liver disease, and it is linked to elevated cardiovascular- and cancer-related morbidity and mortality. Insulin resistance related to metabolic syndrome is the main pathogenic trigger that, in association with adverse genetic, lifestyle, and other factors, precipitates the development of non-alcoholic fatty liver disease. Biochemical markers and radiological imaging, along with liver biopsy in selected cases, help in the disease&rsquo;s diagnosis and prognostication. Weight loss is the cornerstone treatment of non-alcoholic fatty liver disease; however, it is difficult to achieve and maintain, so pharmacotherapy was developed. The remarkable evolution in understanding disease pathogenesis has led to the development of new medical therapies and even the modification of currently available ones. This review summarizes recent advances in understanding the epidemiology, natural history, pathogenesis, diagnosis, and management of non-alcoholic fatty liver disease.">
            <meta name="citation_keywords" content="Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, cirrhosis, fibrosis">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Somaya Albhaisi">
            <meta name="citation_author_institution" content="The Division of Internal Medicine, Virginia Commonwealth University, Richmond, USA">
            <meta name="citation_author" content="Arun Sanyal">
            <meta name="citation_author_institution" content="The Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, USA">
            <meta name="citation_publication_date" content="2018/06/11">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="720">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.14421.1">
            <meta name="citation_firstpage" content="720">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-720/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-720.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=15697 /> <input type=hidden id=articleId name=articleId value=14421 /> <input type=hidden id=xmlUrl value="/articles/7-720/v1/xml"/> <input type=hidden id=xmlFileName value="-7-720-v1.xml"> <input type=hidden id=article_uuid value=672f1458-2272-408a-a8f3-951aed5ac6fd /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in understanding and managing non-alcoholic fatty liver disease"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.14421.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.14421.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-720"
  },
  "headline": "Recent advances in understanding and managing non-alcoholic fatty liver disease",
  "datePublished": "2018-06-11T09:09:25",
  "dateModified": "2018-06-11T09:09:25",
  "author": [
    {
      "@type": "Person",
      "name": "Somaya Albhaisi"
    },    {
      "@type": "Person",
      "name": "Arun Sanyal"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Non-alcoholic fatty liver disease is a leading cause of chronic liver disease that can lead to cirrhosis, hepatocellular cancer, and end-stage liver disease, and it is linked to elevated cardiovascular- and cancer-related morbidity and mortality. Insulin resistance related to metabolic syndrome is the main pathogenic trigger that, in association with adverse genetic, lifestyle, and other factors, precipitates the development of non-alcoholic fatty liver disease. Biochemical markers and radiological imaging, along with liver biopsy in selected cases, help in the disease&rsquo;s diagnosis and prognostication. Weight loss is the cornerstone treatment of non-alcoholic fatty liver disease; however, it is difficult to achieve and maintain, so pharmacotherapy was developed. The remarkable evolution in understanding disease pathogenesis has led to the development of new medical therapies and even the modification of currently available ones. This review summarizes recent advances in understanding the epidemiology, natural history, pathogenesis, diagnosis, and management of non-alcoholic fatty liver disease."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-720.html",
            "name": "Recent advances in understanding and managing non-alcoholic fatty..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in understanding and managing non-alcoholic fatty... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=15697 data-id=14421 data-downloads="" data-views="" data-scholar="10.12688/f1000research.14421.1" data-recommended="" data-doi="10.12688/f1000research.14421.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-720/v1/pdf?article_uuid=672f1458-2272-408a-a8f3-951aed5ac6fd" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-14421-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-14421-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-14421-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Albhaisi S and Sanyal A. Recent advances in understanding and managing non-alcoholic fatty liver disease [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):720 (<a class=new-orange href="https://doi.org/10.12688/f1000research.14421.1" target=_blank>https://doi.org/10.12688/f1000research.14421.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-14421-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=14421 id=track-article-signin-14421 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/14421?target=/articles/7-720.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=15697 /> <input name=articleId type=hidden value=14421 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in understanding and managing non-alcoholic fatty liver disease</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:somaya.albhaisi@vcuhealth.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Somaya Albhaisi</span></a><sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:arun.sanyal@vcuhealth.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Arun Sanyal</span></a><sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:somaya.albhaisi@vcuhealth.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Somaya Albhaisi</span></a><sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:arun.sanyal@vcuhealth.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Arun Sanyal</span></a><sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 11 Jun 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.14421.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> The Division of Internal Medicine, Virginia Commonwealth University, Richmond, USA<br/> <sup>2</sup> The Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, USA<br/> <p> <div class=margin-bottom> Somaya Albhaisi <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Arun Sanyal <br/> <span>Roles: </span> Conceptualization, Methodology, Resources, Supervision, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=35210-34745></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=35211-34746></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Non-alcoholic fatty liver disease is a leading cause of chronic liver disease that can lead to cirrhosis, hepatocellular cancer, and end-stage liver disease, and it is linked to elevated cardiovascular- and cancer-related morbidity and mortality. Insulin resistance related to metabolic syndrome is the main pathogenic trigger that, in association with adverse genetic, lifestyle, and other factors, precipitates the development of non-alcoholic fatty liver disease. Biochemical markers and radiological imaging, along with liver biopsy in selected cases, help in the disease’s diagnosis and prognostication. Weight loss is the cornerstone treatment of non-alcoholic fatty liver disease; however, it is difficult to achieve and maintain, so pharmacotherapy was developed. The remarkable evolution in understanding disease pathogenesis has led to the development of new medical therapies and even the modification of currently available ones. This review summarizes recent advances in understanding the epidemiology, natural history, pathogenesis, diagnosis, and management of non-alcoholic fatty liver disease. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, cirrhosis, fibrosis </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Somaya Albhaisi (<a href="mailto:somaya.albhaisi@vcuhealth.org">somaya.albhaisi@vcuhealth.org</a>) <br> Arun Sanyal (<a href="mailto:arun.sanyal@vcuhealth.org">arun.sanyal@vcuhealth.org</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding authors:</b> Somaya Albhaisi, Arun Sanyal </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2018 Albhaisi S and Sanyal A. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Albhaisi S and Sanyal A. Recent advances in understanding and managing non-alcoholic fatty liver disease [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):720 (<a href="https://doi.org/10.12688/f1000research.14421.1" target=_blank>https://doi.org/10.12688/f1000research.14421.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 11 Jun 2018, <b>7</b>(F1000 Faculty Rev):720 (<a href="https://doi.org/10.12688/f1000research.14421.1" target=_blank>https://doi.org/10.12688/f1000research.14421.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 11 Jun 2018, <b>7</b>(F1000 Faculty Rev):720 (<a href="https://doi.org/10.12688/f1000research.14421.1" target=_blank>https://doi.org/10.12688/f1000research.14421.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d5208e169>Introduction</h2><p class="" id=d5208e172>Non-alcoholic fatty liver disease (NAFLD) is the condition in which hepatic fat accumulation is present after all other causes of hepatic steatosis are excluded; these include liver disease caused by other factors, excessive alcohol consumption, and other conditions that may lead to hepatic steatosis. The clinical spectrum of NAFLD is wide-ranging and spans NAFL to non-alcoholic steatohepatitis (NASH), advanced fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). NAFLD is the most common liver disease in the world, and NASH may soon become the most common indication for liver transplantation<sup><a href="#ref-1">1</a></sup>. The incidence and prevalence of NAFLD is rising globally owing to increasing rates of obesity and diabetes<sup><a href="#ref-2">2</a>,<a href="#ref-3">3</a></sup>. The development of liver cancer in patients with NAFLD, even without the presence of cirrhosis, was observed recently in a number of studies. These outcomes contribute substantially to the burden of disease to the individual and also to society. It is therefore a public health priority to develop effective measures for the identification and treatment of this condition. The recent advances in understanding and managing NAFLD are reviewed below.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5208e189>Epidemiology</h2><p class="" id=d5208e192>The true worldwide incidence rate of NAFLD/NASH is not known. It was found through a few studies that the incidence rates were widely variable owing to multiple factors which include the different characteristics of study populations, exclusion criteria, study methodology, and approach for diagnosis. The variable presentations of the disease as well as the unavailability of sensitive diagnostic studies besides the liver biopsy, which remains the gold standard to date, probably contribute to the underreported incidence and prevalence of NAFLD<sup><a href="#ref-4">4</a></sup>. Analysis of liver ultrasound data collected between 1988 and 1994 from the Third National Health and Nutrition Examination Survey (NHANES III) reported that 19% of adults have NAFLD, while a meta‐analysis of studies from 2006–2014 estimated a NAFLD prevalence of 24% (20–29%) in the general population. The Dionysos<sup><a href="#ref-5">5</a></sup> study in Italy first reported that the global prevalence of NAFLD is 24–25% of the general population; this is the most accurate estimated figure to date, and it was confirmed recently by Younossi<sup><a href="#ref-6">6</a>,<a href="#ref-7">7</a></sup>, who described some regional differences with the highest rates reported in South America and the Middle East, followed by Asia, the USA, and Europe. The increasing prevalence of NAFLD/NASH is in parallel to the pandemic spread of obesity, diabetes mellitus (DM), and metabolic syndrome. One-third of American adults are thought to have NAFLD<sup><a href="#ref-8">8</a></sup>. The prevalence of NAFLD in Europe and the Middle East ranges from 20–30%. The highest prevalence of NAFLD was reported in South America and the Middle East, whereas the lowest was reported in Africa. Although the global burden of NAFLD is unknown, on the basis of the above studies, we estimate that ~one billion individuals have NAFLD at the current time. Liver biopsy is the gold-standard diagnostic test. There are also some non-invasive diagnostic modalities including hepatic ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI). The discrepancy in prevalence data for NAFLD could be attributed to the difference in sensitivity of these diagnostic tests. Younossi <i>et al</i>. reported that the pooled regional NAFLD prevalence estimates among patients diagnosed by blood test were 13.00% (95% confidence interval [CI]: 4.44–32.47) for Europe, 12.89% (95% CI: 8.32–19.44) for North America, and 9.26% (95% CI: 7.07–12.05) for Asia<sup><a href="#ref-9">9</a></sup>. Estes <i>et al</i>. reported that by 2030, the NAFLD population was projected to increase by 21% to 100.9 million cases. Prevalence in 2030 is estimated at 33.5% (aged ≥15 years) and 28.4% (all ages). The NAFLD population is estimated to have a median age of 50 (2015), which increases to 55 by 2030. During 2015–2030, there would be 1.2 prevalent NAFLD cases among male individuals for every 1.0 among female individuals<sup><a href="#ref-10">10</a></sup>. Because of the small number of studies that contained NAFLD incidence results, Younossi <i>et al</i>.’s meta-analysis results were obtained only for Asia (only available for China and Japan) and Israel. In Asia, the pooled regional NAFLD incidence rate was estimated to be 52.34 per 1,000 person-years (95% CI: 28.31–96.77), and in Israel it was estimated to be 28.01 per 1,000 person-years (95% CI: 19.34–40.57)<sup><a href="#ref-9">9</a></sup>. According to Estes <i>et al</i>., the fastest growth in obesity prevalence occurred during 2000–2002. In comparison, the fastest growth in DM prevalence occurred during 2012–2014. The number of NAFLD cases increased following obesity, resulting in a peak NAFLD incidence in 2008 with an estimated 4.17 million new cases. Since then, a slowing rate of increase in NAFLD was forecasted, and new cases were estimated to decline to 3.62 million annually. Thus, the total number of NAFLD cases is still increasing but at a lower rate compared to the 2005–2008 period. However, given the rising prevalence of type 2 diabetes, the proportion of individuals with NASH is predicted to increase, and with prolonged disease exposure the number of individuals with end-stage liver disease is likely to triple by 2030. It has been estimated that, in the USA, NAFLD is responsible for $292 billion in annual medical and societal costs<sup><a href="#ref-10">10</a></sup>. The projected cost of caring for patients is expected to increase by 18% from 2000 to 2035, and the health-related quality of life of NAFLD patients is described as declining<sup><a href="#ref-11">11</a>,<a href="#ref-12">12</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5208e254>Pathogenesis</h2><p class="" id=d5208e257>A substantial body of literature has accumulated and provides a framework to understand the pathogenesis of NAFLD. With increasing caloric intake and changes in dietary composition, excess calories are stored as fat within adipose tissue and also induce changes in the microbiome. This triggers changes in intestinal permeability and increased systemic exposure to intestinal microbial products, triggering activation of the innate immune system and adipose tissue inflammation. The metabolic consequence is the development of an insulin-resistant state. The insulin-resistant state which drives increased lipolysis along with the consumption of excess calories deliver an increased load of lipotoxic lipids including free fatty acids to the liver along with excess carbohydrates. This is further compounded by increased <i>de novo</i> lipogenesis, which is driven by hyperinsulinemia and retained sensitivity to the lipogenic effects of insulin in an otherwise insulin-resistant state. The liver attempts to react by increasing lipid oxidation and export of lipids; when lipid influx and synthesis exceed its metabolism and export, the excess lipids accumulate in lipid droplets, creating a fatty liver. Recently, it has been shown that the PNPLA3 protein accumulates on the surface of lipid droplets<sup><a href="#ref-13">13</a></sup>. Under conditions of lipotoxic stress, proteasomal impairment drives such accumulation where, in those with mutant PNPLA3, impaired lipolysis leads to further accumulation of fat. However, this does not explain how the mutation drives the development of steatohepatitis and cirrhosis. Cell stress including oxidative stress and unfolded protein response can trigger apoptosis, cell death, and inflammation. Apoptosis can also trigger cell regenerative activity. While much is known about how lipotoxicity drives cell death and inflammation, there is still a paucity of information on the biological mechanisms driving tissue adaptation and regeneration. Prolonged inflammation drives fibrogenic remodeling of the liver. Recently, considerable advances in the development of <i>in vivo</i> and <i>in vitro</i> models of NASH have been made<sup><a href="#ref-14">14</a>–<a href="#ref-16">16</a></sup>. The criteria for the validation of such models as models of human NASH are clearer<sup><a href="#ref-17">17</a></sup>. In reviewing data from such models for understanding human disease, it is important to ascertain if such validations have been performed in the model. These criteria include whether gene manipulations that are not reflective of the human state are used, if the macronutrient composition reflects human diet, if features commonly seen in humans such as obesity, systemic inflammation, dyslipidemia, insulin resistance, steatohepatitis, and fibrosis are present, and if there is concordance of cell signaling and transcriptome to human disease.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5208e288>Natural history and outcome of non-alcoholic fatty liver disease</h2><p class="" id=d5208e291>Most of the data on the natural history of NAFLD are based on indirect evidence and have come from a selected population. Despite NAFLD’s high prevalence, only a minority of NAFLD patients progress to significant fibrosis or experience associated morbidity<sup><a href="#ref-18">18</a></sup>. The reason for this variability is, partly, subtle individual genetic differences that change one’s response to environmental factors and lifestyle, thus determining disease phenotype<sup><a href="#ref-19">19</a>–<a href="#ref-21">21</a></sup>. Recent data from a population study in Olmsted County reported a significantly higher mortality in NAFLD patients compared with the general population; however, overall mortality and liver-related death were lower than previously reported from referral centers. Mortality in these patients was associated with older age, glucose intolerance/diabetes, and the presence of cirrhosis. The top three leading causes of death in patients with NAFLD in descending order are cardiovascular disease, cancer, and liver disease<sup><a href="#ref-22">22</a></sup>. A patient’s chance of progressing to advanced liver disease, including hepatic decompensation and HCC, is higher if they suffer from NASH than if they suffer from NAFLD. Recent studies have suggested that NAFLD can evolve to NASH with advanced fibrosis, which would imply that it may not be an entirely benign condition<sup><a href="#ref-23">23</a>,<a href="#ref-24">24</a></sup>. A recent study found that 44% of patients with NAFLD at the index liver biopsy progressed to NASH and 37% progressed to fibrosis, including 22% to advanced degree<sup><a href="#ref-25">25</a></sup>. Managing NAFLD requires markedly increased healthcare resources as fibrosis worsens, especially after the development of cirrhosis. Although there are no exact models to estimate the incidence and the disease burden of NAFLD in the next few years, the changing trends of obesity and DM suggest that this problem is increasing worldwide and might place a growing strain on healthcare systems.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5208e323>Diagnosis</h2><p class="" id=d5208e326>NAFLD remains asymptomatic in a significant proportion of patients, and the diagnosis is often suspected when liver functions are found to be abnormal on biochemical testing or hepatic imaging (ultrasonography, CT, or MRI of liver) suggests fatty liver when performed for some other reason. Liver biopsy remains the gold standard for diagnostic evaluation of NAFLD. In the past, the NASH Clinical Research Network histological scoring system was the most widely used, representing a validated scoring system that generates a NAFLD activity score (NAS). A NAS of 5 or more is sometimes considered NASH and less than 3 is considered not NASH<sup><a href="#ref-26">26</a></sup>. However, NAS cannot be used as a surrogate for discrimination between NASH and NAFLD, although it is useful for the histological diagnosis<sup><a href="#ref-27">27</a>,<a href="#ref-28">28</a></sup>. Given that the prevalence of NAFLD is high, using liver biopsy to detect fibrosis-cirrhosis is unfeasible. The accuracy of liver biopsy to assess fibrosis has also been questioned owing to sampling errors and intra- and inter-observer variability that may lead to over- or under-staging. Cost, procedure-related complications, and intra- and inter-observer variations in reporting the histology are the major drawbacks of liver biopsy, and, therefore, it is usually not recommended in clinical practice, except in circumstances where other differential diagnoses are to be excluded. Over the past decade, there has been a growing interest in alternative novel strategies for the non-invasive evaluation of fibrosis. These techniques require two distinct but complementary approaches: the measurement of serum biomarkers or the estimation of liver stiffness using ultrasound-based elastography with transient elastography (TE) as the forerunner<sup><a href="#ref-29">29</a></sup>. In NAFLD patients, TE, the fibrosis index (FIB-4), and NAFLD fibrosis scores are the best validated non-invasive tests<sup><a href="#ref-30">30</a>,<a href="#ref-31">31</a></sup>. For instance, in a recent meta-analysis<sup><a href="#ref-32">32</a></sup> based on 64 studies including a total of 13,046 NAFLD patients, the summary AUROC values of TE, FIB-4, and the NAFLD fibrosis score for diagnosing severe fibrosis-cirrhosis were 0.88, 0.84, and 0.84, respectively. When all three were compared head to head, TE was the most accurate in the diagnosis of cirrhosis<sup><a href="#ref-33">33</a></sup>. Lastly, recent evidence shows that non-invasive tests, including FIB-4 and NAFLD fibrosis score as well as TE-derived liver stiffness measurements, accurately identify the subgroup of patients with NAFLD at a higher risk of developing liver-related complications and death or liver transplantation<sup><a href="#ref-34">34</a></sup>. Liver enzymes can often be normal in a number of patients with NAFLD. Although several biochemical markers, such as TNF-a, IL-6, CRP, pentraxin, ferritin, serum prolidase enzyme activity, soluble receptor for advanced glycation end product, and cytokeratin-18, have been proposed as useful in predicting the severity of NAFLD/NASH in the past, none of these markers have shown sufficient sensitivity or specificity for routine clinical application for diagnosis<sup><a href="#ref-35">35</a></sup>. Ultrasonography, CT, and MRI of the liver are the standard imaging modalities used in clinical practice for the diagnosis of NAFLD. In general, about 30% of liver steatosis cases should be present for sonography to detect NAFLD. TE is an ultrasound-based imaging technique to detect the degree of fibrosis in patients with NAFLD and NASH. The sensitivity and specificity of TE to diagnose various stages of fibrosis have been reported to be 79–92% and 75–92%, respectively<sup><a href="#ref-36">36</a></sup>. Recent evidence also suggests that the ultrasound-based controlled attenuation parameter value used in the TE technique can predict the degree of steatosis in patients with NAFLD<sup><a href="#ref-37">37</a></sup>. The gold standard for the non-invasive assessment of hepatic steatosis is the use of MRI protein density fat fraction. Newer MRI techniques, such as MR elastography, can stage the degree of fibrosis non-invasively to diagnose and assess the prognosis of patients with NAFLD<sup><a href="#ref-38">38</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5208e384>Treatment</h2><p class="" id=d5208e387>Lifestyle modification, consisting of diet and exercise, is the cornerstone of therapy for NAFLD and has been shown by many studies to improve liver histology<sup><a href="#ref-39">39</a>,<a href="#ref-40">40</a></sup>. However, lifestyle modification is difficult to achieve and to sustain<sup><a href="#ref-41">41</a></sup>. The remarkable progress that has been made in previous years in understanding disease pathogenesis has led to an explosion of medical therapies targeting various aspects of the fat accumulation and injury pathways. These therapies can be classified according to their intended targets into four general groups (<a href="#f1">Figure 1</a>).</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/15697/b14d25bc-74c5-4c88-b7d9-4127d681ae49_figure1.gif"><img alt="b14d25bc-74c5-4c88-b7d9-4127d681ae49_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/15697/b14d25bc-74c5-4c88-b7d9-4127d681ae49_figure1.gif"></a><div class=caption><h3>Figure 1. Targets of upcoming therapies for non-alcoholic fatty liver disease (NAFLD).</h3><p id=d5208e414>DNL, <i>de novo</i> lipogenesis; FGF, fibroblast growth factor; FMT, fecal microbial transplant; FXR, farnesoid X receptor; FXRE, FXR response element; GHRH, growth hormone-releasing hormone; GLP-1, glucagon-like peptide-1; PPAR, peroxisome proliferator-activated receptor; PPRE, PPAR response element; RXR, retinoid X receptor. Reprinted with permission from Rotman Y and Sanyal AJ. <i>Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease</i>. Gut. 2017;66:180–190.</p></div></div><div class=section><a name=d5208e427 class=n-a></a><h3 class=section-title>1. Targeting metabolism and oxidative stress</h3><p class="" id=d5208e432><b><i>Antioxidants</i></b>. Large randomized clinical trials have proven the beneficial effects of vitamin E in patients with NASH (<a href="#T1">Table 1</a>). In an innovative randomized double-blind placebo-controlled trial (RDBPCT), the authors found that a daily dose of 800 IU of vitamin E for 96 weeks improved the histological features of NASH (hepatic steatosis, lobular inflammation, and hepatocellular ballooning) in approximately 43% of non-diabetic patients compared with 19% of placebo (<i>P</i> = 0.001)<sup><a href="#ref-42">42</a></sup>. In an analysis conducted recently of patients from the control group of the FLINT trial, vitamin E’s ability to improve NASH histological features was further confirmed<sup><a href="#ref-43">43</a>,<a href="#ref-44">44</a></sup>.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Clinical trials of medications for non-alcoholic fatty liver disease (NAFLD).</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d5208e466 class=n-a></a><thead><a name=d5208e468 class=n-a></a><tr><a name=d5208e470 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d5208e472 class=n-a></a>Medication</th><th align=left colspan=1 rowspan=1 valign=top><a name=d5208e475 class=n-a></a>Mechanism</th><th align=left colspan=1 rowspan=1 valign=top><a name=d5208e478 class=n-a></a>Current status</th><th align=left colspan=1 rowspan=1 valign=top><a name=d5208e481 class=n-a></a>Study identifier</th></tr></thead><tbody><a name=d5208e486 class=n-a></a><tr><a name=d5208e488 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e490 class=n-a></a>Pioglitazone</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e493 class=n-a></a>PPARγ agonist</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e496 class=n-a></a>Phase IV (completed)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e499 class=n-a></a>NCT00994682</td></tr><tr><a name=d5208e503 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e505 class=n-a></a>Elafibranor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e508 class=n-a></a>PPARα/δ agonist</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e511 class=n-a></a>Phase III (recruiting)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e514 class=n-a></a>NCT02704403</td></tr><tr><a name=d5208e518 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e520 class=n-a></a>Saroglitazar</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e523 class=n-a></a>PPARα/γ agonist</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e526 class=n-a></a>Phase II (recruiting)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e529 class=n-a></a>NCT03061721</td></tr><tr><a name=d5208e533 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e535 class=n-a></a>Obeticholic acid</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e538 class=n-a></a>FXR agonist</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e541 class=n-a></a>Phase III (recruiting)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e544 class=n-a></a>NCT03439254</td></tr><tr><a name=d5208e548 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e550 class=n-a></a>Liraglutide</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e553 class=n-a></a>GLP-1 receptor agonist</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e556 class=n-a></a>Phase IV (completed)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e559 class=n-a></a>NCT02147925</td></tr><tr><a name=d5208e564 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e566 class=n-a></a>Aramchol</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e569 class=n-a></a>SCD inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e572 class=n-a></a>Phase II (recruiting)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e575 class=n-a></a>NCT02684591</td></tr><tr><a name=d5208e579 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e581 class=n-a></a>Volixibat (SHP-626)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e584 class=n-a></a>ASBT inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e587 class=n-a></a>Phase II (recruiting)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e590 class=n-a></a>NCT02787304</td></tr><tr><a name=d5208e594 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e596 class=n-a></a>BMS-986036</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e599 class=n-a></a>FGF-21 analogue</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e602 class=n-a></a>Phase II (not yet recruiting)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e605 class=n-a></a>NCT03486899</td></tr><tr><a name=d5208e609 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e611 class=n-a></a>NGM-282</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e614 class=n-a></a>FGF-19 analogue</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e617 class=n-a></a>Phase II (recruiting)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e620 class=n-a></a>NCT02443116</td></tr><tr><a name=d5208e624 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e626 class=n-a></a>Tesamorelin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e629 class=n-a></a>GHRH analogue</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e632 class=n-a></a>Phase II (not yet recruiting)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e635 class=n-a></a>NCT03375788</td></tr><tr><a name=d5208e639 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e641 class=n-a></a>NDI-010976</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e644 class=n-a></a>ACC inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e647 class=n-a></a>Phase I (completed)</td><td colspan=1 rowspan=1><a name=d5208e650 class=n-a></a></td></tr><tr><a name=d5208e654 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e656 class=n-a></a>GS-9674</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e659 class=n-a></a>FXR agonist</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e662 class=n-a></a>Phase I (recruiting)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e665 class=n-a></a>NCT02808312</td></tr><tr><a name=d5208e669 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e671 class=n-a></a>Dur-928</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e674 class=n-a></a>Sulfated oxysterol</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e677 class=n-a></a>Phase I </td><td colspan=1 rowspan=1><a name=d5208e680 class=n-a></a></td></tr><tr><a name=d5208e683 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e685 class=n-a></a>AZD4076</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e688 class=n-a></a>miR-103/-107 antagonist</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e691 class=n-a></a>Phase I (active, not recruiting)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e694 class=n-a></a>NCT02612662</td></tr><tr><a name=d5208e698 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e700 class=n-a></a>Rosuvastatin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e703 class=n-a></a>HMG-CoA reductase<br class=br>inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e708 class=n-a></a>Phase IV (not yet recruiting)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e711 class=n-a></a>NCT03434613</td></tr><tr><a name=d5208e715 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e717 class=n-a></a>INT-767</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e720 class=n-a></a>FXR/TGR5 agonist</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e723 class=n-a></a>Preclinical</td><td colspan=1 rowspan=1><a name=d5208e726 class=n-a></a></td></tr><tr><a name=d5208e729 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e731 class=n-a></a>Sevelamer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e734 class=n-a></a>Bile acid sequestrant</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e737 class=n-a></a>Preclinical</td><td colspan=1 rowspan=1><a name=d5208e740 class=n-a></a></td></tr><tr><a name=d5208e744 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e746 class=n-a></a>Vitamin E</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e749 class=n-a></a>Anti-oxidant</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e752 class=n-a></a>Phase II (active, not recruiting)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e755 class=n-a></a>NCT01792115</td></tr><tr><a name=d5208e759 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e761 class=n-a></a>Pentoxifylline</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e764 class=n-a></a>PDE inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e767 class=n-a></a>Phase II (completed)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e770 class=n-a></a>NCT02283710</td></tr><tr><a name=d5208e774 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e776 class=n-a></a>Cenicriviroc</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e779 class=n-a></a>CCR2/CCR5 antagonist</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e782 class=n-a></a>Phase II (enrolling by invitation)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e785 class=n-a></a>NCT03059446</td></tr><tr><a name=d5208e789 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e791 class=n-a></a>Emricasan</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e794 class=n-a></a>Caspase inhibitors</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e797 class=n-a></a>Phase II (recruiting)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e800 class=n-a></a>NCT03205345</td></tr><tr><a name=d5208e804 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e806 class=n-a></a>GS-4997</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e809 class=n-a></a>ASK1 inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e812 class=n-a></a>Phase III (active, not recruiting)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e815 class=n-a></a>NCT03053050</td></tr><tr><a name=d5208e819 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e821 class=n-a></a>Amlexanox</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e824 class=n-a></a>IKKε/TBK1 inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e827 class=n-a></a>Phase II (active, not recruiting)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e830 class=n-a></a>NCT01975935</td></tr><tr><a name=d5208e835 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e837 class=n-a></a>PXS-4728A</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e840 class=n-a></a>VAP-1 inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e843 class=n-a></a>Phase I (completed)</td><td colspan=1 rowspan=1><a name=d5208e846 class=n-a></a></td></tr><tr><a name=d5208e849 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e851 class=n-a></a>Orlistat</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e854 class=n-a></a>Intestinal lipase inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e857 class=n-a></a>Phase IV (completed)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e860 class=n-a></a>NCT00160407</td></tr><tr><a name=d5208e864 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e866 class=n-a></a>IMM-124e</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e869 class=n-a></a>IgG-rich bovine<br class=br>colostrum</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e874 class=n-a></a>Phase II (recruiting)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e877 class=n-a></a>NCT03042767</td></tr><tr><a name=d5208e881 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e883 class=n-a></a>Solithromycin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e886 class=n-a></a>Antibiotic</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e889 class=n-a></a>Phase II (completed)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e892 class=n-a></a>NCT02510599</td></tr><tr><a name=d5208e896 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e898 class=n-a></a>Fecal microbial<br class=br>transplant</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e903 class=n-a></a>Modulation of gut<br class=br>microbiome</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e908 class=n-a></a>Phase II (active, not recruiting)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e911 class=n-a></a>NCT02496390</td></tr><tr><a name=d5208e915 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e917 class=n-a></a>Simtuzumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e920 class=n-a></a>LOXL2 antibody</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e923 class=n-a></a>Phase II (completed)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e926 class=n-a></a>NCT02466516</td></tr><tr><a name=d5208e931 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e933 class=n-a></a>GR-MD-02</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e936 class=n-a></a>Galectin-3 inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e939 class=n-a></a>Phase II (completed)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5208e942 class=n-a></a>NCT02421094</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d5208e950 class=n-a></a><p id=d5208e952> ACC, acetyl-CoA carboxylase; ASBT, apical sodium-dependent bile acid transporter; ASK1, apoptosis signal-regulating kinase 1; CCR, C-C chemokine receptor; GLP, glucagon-like peptide; FGF, fibroblast growth factor; FXR, farnesoid X receptor; GHRH, growth hormone-releasing hormone; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-coenzyme A; LOXL2, lysyl oxidase-like 2; miR, microRNA; PDE, phosphodiesterase; PPAR, peroxisome proliferator-activator receptor; SCD, stearoyl CoA desaturase; TBK1, TANK-binding kinase 1; VAP, vascular adhesion protein.</p></div></div></div><p class="" id=d5208e958><b><i>Lipid-lowering agents</i></b>. A recent study demonstrated the underutilization of statins in patients with NAFLD<sup><a href="#ref-45">45</a></sup> (<a href="#T1">Table 1</a>). A prospective trial in 20 patients with biopsy-proven NASH and dyslipidemia determined the effect of 12 months of rosuvastatin (10 mg/day) on liver histology. In total, 19 out of the 20 patients enrolled demonstrated complete resolution of NASH despite no change in weight compared with baseline<sup><a href="#ref-46">46</a></sup>. Aramchol is a synthetic lipid that inhibits the stearoyl coenzyme A desaturase 1, a key enzyme in lipid metabolism<sup><a href="#ref-47">47</a></sup>. A recent phase II RDBPCT compared two doses of aramchol (100 mg and 300 mg, daily) to placebo for three months in 60 patients with biopsy-proven NAFLD including six with NASH. At the end of the trial, hepatic fat was significantly reduced, as measured by magnetic resonance spectroscopy, in patients who were treated with 100 mg daily aramchol compared to those given placebo (12.57% versus 6.39%, respectively; <i>P</i> = 0.02)<sup><a href="#ref-48">48</a></sup>.</p><p class="" id=d5208e987><b><i>Targeting insulin resistance</i></b></p><p class="" id=d5208e993><b>Bile-acid-based insulin sensitization</b></p><p class="" id=d5208e997>Farnesoid X receptor (FXR) is a nuclear bile acid receptor which inhibits further bile acid production when activated via the rate-limiting enzyme cholesterol 7 alpha-hydroxylase (CYP7A1) (<a href="#T1">Table 1</a>). A recent study demonstrated that there are changes in the bile acid composition in those with NASH<sup><a href="#ref-49">49</a></sup>. There is a progressive increase in primary bile acids and a decrease in secondary bile acids, which would be predicted to reduce FXR effects.</p><p class="" id=d5208e1007>Obeticholic acid (OCA) is a selective FXR agonist that showed promising anti-inflammatory and anti-fibrotic effects in animal studies<sup><a href="#ref-50">50</a></sup>. Its potential has been realized in the FLINT trial, where it was shown to be superior to placebo for the reduction of disease activity as well as fibrosis. It also increases LDL cholesterol and causes pruritus in up to 20% of individuals. This has led to efforts to develop small molecules as FXR agonists that do not have these adverse effects. Several such compounds are in early phase trials. It is also proposed that binding of FXR by bile acids in the intestine releases FGF19, which also ameliorates NASH; a recent early phase trial demonstrated rapid de-fatting of the liver with FGF19. On the other hand, blocking bile acid re-absorption in the ileum also depletes the bile acid pool and pulls cholesterol into bile acid synthesis, decreasing the cholesterol load. Further delivery of bile acids to the ileum can release GLP1, which has insulin-sensitizing properties. The use of bile acid transport inhibitors is being tested in clinical trials.</p><p class="" id=d5208e1014>Recently, a number of additional bile acid receptors have been proposed as targets for drug development in NASH. TGR5 is a receptor with important functions and effects on hepatic lipid regulation and glucose metabolism. INT-767 is an investigation drug which activates both FXR and TGR5 and is being studied currently in phase IIb RDBPCT in patients with NASH (NCT02854605).</p><p class="" id=d5208e1017><b><i>Peroxisome proliferator-activator receptors</i></b>. Recently, a peroxisome proliferator-activated receptor (PPAR) δ agonist, MBX-8025, was shown to abolish lipotoxicity and ameliorate NASH in a diabetic mouse model<sup><a href="#ref-51">51</a></sup>. Elafibranor (GFT-505) is a dual PPARα/δ agonist which has been shown to improve liver, adipose tissue, and peripheral tissue insulin sensitivity and reduce alanine aminotransferase (ALT) levels in patients with metabolic syndrome<sup><a href="#ref-52">52</a></sup>. Thiazolidinediones, including pioglitazone, are PPARγ agonists used in the treatment of diabetes and have been demonstrated to be effective in NASH<sup><a href="#ref-53">53</a></sup>.</p><p class="" id=d5208e1035>The glitazars are dual PPARα/γ agonists which aim to combine the beneficial effects of activating both PPAR receptors. In a mouse model of NASH, saroglitazar was found to reduce steatosis and ALT as well as improve liver histology<sup><a href="#ref-54">54</a></sup>. A subsequent retrospective study of NAFLD patients with dyslipidemia treated with saroglitazar for 24 weeks showed a significant decrease in ALT compared with baseline<sup><a href="#ref-55">55</a></sup>. A phase II open-label study (PRESS VIII) evaluated the effectiveness of saroglitazar among 32 patients with biopsy-proven NASH<sup><a href="#ref-54">54</a></sup>. After 12 weeks of treatment, a 52% decrease in ALT was shown. A phase III RDBPCT is currently ongoing in India to assess the effect of saroglitazar versus placebo for 52 weeks in biopsy-proven non-cirrhotic NASH (Clinical Trials Registry-India CTRI/2015/10/006236) (<a href="#T1">Table 1</a>).</p><p class="" id=d5208e1054><b><i>Metformin</i></b>. A recent meta-analysis has shown that metformin leads to normalization of serum aminotransferases in a significantly greater proportion of patients when compared to dietary changes, and it also improved steatosis on imaging<sup><a href="#ref-56">56</a></sup>.</p><p class="" id=d5208e1064><b><i>Incretins and sodium–glucose cotransporter 2 inhibitors</i></b>. Recently, a multicenter RDBPCT evaluated liraglutide in 52 subjects with NASH. After 48 weeks of treatment, NASH resolved in 39% of patients treated with subcutaneous liraglutide injections compared to only 9% in the placebo group (relative risk 4.3 [95% CI: 1.0–17.7]; <i>P</i> = 0.019). Additionally, two patients on liraglutide (9%) versus eight patients (36%) on placebo exhibited fibrosis progression<sup><a href="#ref-57">57</a></sup>. The newest class of diabetic medications on the market are sodium–glucose cotransporter 2 (SGLT-2) inhibitors. A recent retrospective study evaluated the effectiveness of SGLT-2 inhibitor ipragliflozin (50 mg/day) on liver enzymes and FIB-4 in 50 diabetic NAFLD patients<sup><a href="#ref-58">58</a></sup>. Over an average follow-up of 451 days, there was a significant decrease in body weight, ALT, and FIB-4 compared with baseline values (<a href="#T1">Table 1</a>).</p><p class="" id=d5208e1084><b><i>FGF21</i></b>. This is a hepatokine with insulin-sensitizing and anti-fibrotic properties. In a phase IIa study, daily as well as weekly dosing of FGF21 was associated with improvement in hepatic steatosis and a decrease in hepatic stiffness.</p></div><div class=section><a name=d5208e1091 class=n-a></a><h3 class=section-title>2. Targeting inflammation</h3><p class="" id=d5208e1096>Cenicriviroc (CVC) is an oral dual antagonist of C-C chemokine receptors (CCR2/CCR5) that was recently studied in a phase IIb RDBPCT, the CENTAUR trial. The trial showed improvement of fibrosis by at least one stage (<i>P</i> = 0.023) and a decrease in IL-6, high-sensitivity CRP, and fibrinogen levels in patients treated with CVC compared to placebo. A phase IIa study of cenicriviroc (ORION) aiming to assess the effect of 24 weeks of treatment on insulin sensitivity, liver enzymes, and liver imaging in obese patients with insulin resistance and suspected NAFLD in HIV-infected subjects provided encouraging initial data (NCT02330549). The CENTAUR study by Friedman <i>et al</i>. evaluated the effect of cenicriviroc on the histology of NASH<sup><a href="#ref-59">59</a></sup>; this showed improved biochemical evidence of inflammation and histological evidence of decreased fibrosis. However, it did not affect the presence of steatohepatitis or disease activity as assessed by histological assessment.</p><p class="" id=d5208e1109>Another investigational anti-inflammatory agent is amlexanox; it functions through different mechanisms by inhibiting NFκB-pathway-produced IKKε kinases and TANK-binding kinase 1 (TBK1). This drug, currently used for the treatment of recurrent aphthous ulcers and asthma, is being studied in a phase II RDBPCT in obese patients with type 2 diabetes and NAFLD (NCT01975935) (<a href="#T1">Table 1</a>).</p></div><div class=section><a name=d5208e1117 class=n-a></a><h3 class=section-title>Targeting apoptosis</h3><p class="" id=d5208e1122>Emricasan is a first-in-class caspase protease inhibitor that has been studied in preclinical settings. In a recent phase II RDBPCT of 38 study participants with non-cirrhotic NAFLD, 28 days of emricasan (25 mg twice daily) resulted in a substantial decrease in liver enzymes and cytokeratin 18 fragments, a surrogate of liver apoptosis<sup><a href="#ref-60">60</a></sup>. A phase IIb trial of emricasan versus placebo (ENCORE-NF) is currently ongoing to evaluate the efficacy of 72 weeks of emricasan (10 mg per day or 100 mg per day) in patients with biopsy-proven NASH. The primary outcome is improvement in fibrosis without worsening of NASH (NCT02686762). Inhibition of apoptosis signal-regulating kinase (ASK1) reduces liver steatosis and fibrosis in a murine model of diet-induced NASH<sup><a href="#ref-61">61</a></sup>. An open-label phase II trial in 72 NASH patients with stage 2/3 fibrosis randomized to an oral ASK1 inhibitor, selonsertib (formerly called GS-4997; 6 mg or 18 mg/day), versus lysyl oxidase-like 2 antibody simtuzumab (25 mg subcutaneous weekly) versus selonsertib and simtuzumab was recently completed<sup><a href="#ref-62">62</a></sup>. Preliminary analysis showed that patients who received selonsertib (with or without simtuzumab) were more likely to demonstrate decreased hepatic steatosis, decreased fibrotic stage, and at least 15% decrease in liver stiffness on magnetic resonance elastography compared with simtuzumab alone. Anti-steatotic and anti-fibrotic effects of selonsertib were dose dependent<sup><a href="#ref-63">63</a></sup> (<a href="#T1">Table 1</a>).</p></div><div class=section><a name=d5208e1145 class=n-a></a><h3 class=section-title>3. Targeting fibrosis</h3><p class="" id=d5208e1150>The lysyl oxidase-like 2 antibody simtuzumab is currently in a phase IIb trial in NASH patients with advanced fibrosis but without cirrhosis (NCT01672866) (<a href="#T1">Table 1</a>). Study participants are randomized to biweekly subcutaneous injections of simtuzumab (75 or 120 mg) versus placebo for 96 weeks, followed by an additional 240 weeks of open-label phase. Simtuzumab is also being investigated in a phase IIb trial in NASH patients with compensated cirrhosis (NCT01672879). The primary end point being assessed is mean change in hepatic venous pressure gradient as well as event-free survival. Galectin-3 is a member of a family of proteins that bind to terminal galactose residues on glycoprotein and is found to be increased during acute or chronic inflammation resulting in fibrogenesis. GR-MD-02 is a galectin-3 inhibitor that was shown to improve NASH fibrosis in animal studies<sup><a href="#ref-63">63</a></sup> and is now being evaluated in two phase II RDBPCTs in patients with NASH fibrosis and NASH cirrhosis, one of which has already completed enrollment (NCT02462967, NCT02421094). The final results of a phase II trial indicated that a subset of individuals with mild portal hypertension improved on galectin.</p></div><div class=section><a name=d5208e1161 class=n-a></a><h3 class=section-title>4. Targeting the gut</h3><p class="" id=d5208e1166><b><i>Microbiome-based therapies</i></b>. Bovine colostrum is enriched with IgG directed against antigens injected into cows immediately prior to calving. An IgG-rich bovine colostrum extract, IMM-124e, generated from cows immunized against lipopolysaccharide was shown to improve insulin sensitivity, glycemic control, and liver enzymes in a small pilot study<sup><a href="#ref-64">64</a></sup>. A phase II trial is currently evaluating 24 weeks of IMM-124e on biopsy-proven NASH (ClinicalTrials.gov identifier NCT02316717). Solithromycin, a macrolide antibiotic with anti-inflammatory properties, has been found to improve NASH in animal studies<sup><a href="#ref-65">65</a></sup> and is currently being studied in a phase II clinical trial (NCT02510599) (<a href="#T1">Table 1</a>).</p></div><div class=section><a name=d5208e1184 class=n-a></a><h3 class=section-title>Anti-obesity medications</h3><p class="" id=d5208e1189>A small pilot study suggested that Orlistat-mediated weight loss is associated with reduction in hepatic steatosis<sup><a href="#ref-66">66</a></sup>. However, the impact of Orlistat on steatohepatitis and its ability to slow the progression of NASH to cirrhosis remains unknown (<a href="#T1">Table 1</a>).</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5208e1203>Summary</h2><p class="" id=d5208e1206>NAFLD is the most common cause of chronic liver disease in the Western world today. With rising levels of obesity and type 2 DM, its prevalence will increase in the future and cause considerable morbidity and mortality. The field of NAFLD continues to evolve rapidly. Advances in the understanding of classical steatosis and disease progression are also reviewed with a view toward providing translational insights into how this knowledge can be used to prevent or treat the disease in the future. Despite considerable research and multiple clinical trials, at present no single pharmacologic agent has achieved a clinically meaningful benefit/risk profile to warrant regulatory approval for marketing. There are currently a number of drugs undergoing pivotal trials as potential therapy for NASH. It is anticipated that the first drugs to be approved for NASH will likely become available by 2020. The ideal treatment will lead, in the short term, to a reduction in liver inflammation and fibrosis as well as an improvement in insulin sensitivity and metabolic complications but, in the long term, will need to reduce cardiovascular and liver outcomes.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d5208e1 class=n-a></a><h2 class=main-title id=d5428>Competing interests</h2><p class=metadata-entry><a name=d5208e106 class=n-a></a><p id=d5208e107> No competing interests were disclosed.</p></p></div><div class=back-section><a name=d5208e1 class=n-a></a><h2 class=main-title id=d5430>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d5208e1213 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d5643>References</h2><div class="section ref-list"><a name=d5208e1213 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732415571"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e1220 class=n-a></a>Perumpail BJ, Khan MA, Yoo ER, <i> et al.</i>: Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. <i>World J Gastroenterol.</i> 2017; <b>23</b>(47): 8263–76. <a target=xrefwindow id=d5208e1231 href="http://www.ncbi.nlm.nih.gov/pubmed/29307986">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1234 href="http://dx.doi.org/10.3748/wjg.v23.i47.8263">Publisher Full Text </a> | <a target=xrefwindow id=d5208e1238 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5743497">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732415571">F1000 Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d5208e1251 class=n-a></a>Welsh JA, Karpen S, Vos MB: Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. <i>J Pediatr.</i> 2013; <b>162</b>(3): 496–500.e1. <a target=xrefwindow id=d5208e1259 href="http://www.ncbi.nlm.nih.gov/pubmed/23084707">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1262 href="http://dx.doi.org/10.1016/j.jpeds.2012.08.043">Publisher Full Text </a> | <a target=xrefwindow id=d5208e1265 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3649872">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d5208e1274 class=n-a></a>Eguchi Y, Hyogo H, Ono M, <i> et al.</i>: Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. <i>J Gastroenterol.</i> 2012; <b>47</b>(5): 586–95. <a target=xrefwindow id=d5208e1285 href="http://www.ncbi.nlm.nih.gov/pubmed/22328022">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1288 href="http://dx.doi.org/10.1007/s00535-012-0533-z">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726236127"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e1297 class=n-a></a>Fazel Y, Koenig AB, Sayiner M, <i> et al.</i>: Epidemiology and natural history of non-alcoholic fatty liver disease. <i>Metabolism.</i> 2016; <b>65</b>(8): 1017–25. <a target=xrefwindow id=d5208e1308 href="http://www.ncbi.nlm.nih.gov/pubmed/26997539">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1311 href="http://dx.doi.org/10.1016/j.metabol.2016.01.012">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726236127">F1000 Recommendation</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d5208e1324 class=n-a></a>Bedogni G, Miglioli L, Masutti F, <i> et al.</i>: Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. <i>Hepatology.</i> 2005; <b>42</b>(1): 44–52. <a target=xrefwindow id=d5208e1335 href="http://www.ncbi.nlm.nih.gov/pubmed/15895401">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1338 href="http://dx.doi.org/10.1002/hep.20734">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731251933"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e1348 class=n-a></a>Younossi Z, Anstee QM, Marietti M, <i> et al.</i>: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. <i>Nat Rev Gastroenterol Hepatol.</i> 2018; <b>15</b>(1): 11–20. <a target=xrefwindow id=d5208e1359 href="http://www.ncbi.nlm.nih.gov/pubmed/28930295">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1362 href="http://dx.doi.org/10.1038/nrgastro.2017.109">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731251933">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726043459"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e1375 class=n-a></a>Younossi ZM, Koenig AB, Abdelatif D, <i> et al.</i>: Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. <i>Hepatology.</i> 2016; <b>64</b>(1): 73–84. <a target=xrefwindow id=d5208e1386 href="http://www.ncbi.nlm.nih.gov/pubmed/26707365">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1389 href="http://dx.doi.org/10.1002/hep.28431">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726043459">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d5208e1402 class=n-a></a>Browning JD, Szczepaniak LS, Dobbins R, <i> et al.</i>: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. <i>Hepatology.</i> 2004; <b>40</b>(6): 1387–95. <a target=xrefwindow id=d5208e1413 href="http://www.ncbi.nlm.nih.gov/pubmed/15565570">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1416 href="http://dx.doi.org/10.1002/hep.20466">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d5208e1425 class=n-a></a>Estes C, Razavi H, Loomba R, <i> et al.</i>: Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. <i>Hepatology.</i> 2018; <b>67</b>(1): 123–33. <a target=xrefwindow id=d5208e1436 href="http://www.ncbi.nlm.nih.gov/pubmed/28802062">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1439 href="http://dx.doi.org/10.1002/hep.29466">Publisher Full Text </a> | <a target=xrefwindow id=d5208e1443 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5767767">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726659247"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e1452 class=n-a></a>Younossi ZM, Blissett D, Blissett R, <i> et al.</i>: The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. <i>Hepatology.</i> 2016; <b>64</b>(5): 1577–86. <a target=xrefwindow id=d5208e1463 href="http://www.ncbi.nlm.nih.gov/pubmed/27543837">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1466 href="http://dx.doi.org/10.1002/hep.28785">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726659247">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d5208e1479 class=n-a></a>Martini EM, Garrett N, Lindquist T, <i> et al.</i>: The boomers are coming: a total cost of care model of the impact of population aging on health care costs in the United States by Major Practice Category. <i>Health Serv Res.</i> 2007; <b>42</b>(1 Pt 1): 201–18. <a target=xrefwindow id=d5208e1490 href="http://www.ncbi.nlm.nih.gov/pubmed/17355589">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1493 href="http://dx.doi.org/10.1111/j.1475-6773.2006.00607.x">Publisher Full Text </a> | <a target=xrefwindow id=d5208e1497 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1955745">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d5208e1507 class=n-a></a>Younossi ZM, Henry L: Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease. <i>Pharmacoeconomics.</i> 2015; <b>33</b>(12): 1245–53. <a target=xrefwindow id=d5208e1515 href="http://www.ncbi.nlm.nih.gov/pubmed/26233836">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1518 href="http://dx.doi.org/10.1007/s40273-015-0316-5">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d5208e1527 class=n-a></a>Perla FM, Prelati M, Lavorato M, <i> et al.</i>: The Role of Lipid and Lipoprotein Metabolism in Non-Alcoholic Fatty Liver Disease. <i>Children (Basel).</i> 2017; <b>4</b>(6): pii: E46. <a target=xrefwindow id=d5208e1538 href="http://www.ncbi.nlm.nih.gov/pubmed/28587303">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1541 href="http://dx.doi.org/10.3390/children4060046">Publisher Full Text </a> | <a target=xrefwindow id=d5208e1545 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5483621">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d5208e1554 class=n-a></a>Caldwell SH: Recent Advances in the Treatment of NASH. <i>Gastroenterol Hepatol (N Y).</i> 2006; <b>2</b>(1): 29–31. <a target=xrefwindow id=d5208e1562 href="http://www.ncbi.nlm.nih.gov/pubmed/28210193">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1565 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5307258">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d5208e1574 class=n-a></a>Kanuri G, Bergheim I: <i>In vitro</i> and <i>in vivo</i> models of non-alcoholic fatty liver disease (NAFLD). <i>Int J Mol Sci.</i> 2013; <b>14</b>(6): 11963–80. <a target=xrefwindow id=d5208e1588 href="http://www.ncbi.nlm.nih.gov/pubmed/23739675">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1592 href="http://dx.doi.org/10.3390/ijms140611963">Publisher Full Text </a> | <a target=xrefwindow id=d5208e1595 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3709766">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d5208e1604 class=n-a></a>Feaver RE, Cole BK, Lawson MJ, <i> et al.</i>: Development of an <i>in vitro</i> human liver system for interrogating nonalcoholic steatohepatitis. <i>JCI Insight.</i> 2016; <b>1</b>(20): e90954. <a target=xrefwindow id=d5208e1618 href="http://www.ncbi.nlm.nih.gov/pubmed/27942596">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1622 href="http://dx.doi.org/10.1172/jci.insight.90954">Publisher Full Text </a> | <a target=xrefwindow id=d5208e1625 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5135271">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d5208e1634 class=n-a></a>Morrison MC, Kleemann R, van Koppen A, <i> et al.</i>: Key Inflammatory Processes in Human NASH Are Reflected in Ldlr<sup>-/-</sup>.Leiden Mice: A Translational Gene Profiling Study. <i>Front Physiol.</i> 2018; <b>9</b>: 132. <a target=xrefwindow id=d5208e1648 href="http://www.ncbi.nlm.nih.gov/pubmed/29527177">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1652 href="http://dx.doi.org/10.3389/fphys.2018.00132">Publisher Full Text </a> | <a target=xrefwindow id=d5208e1655 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5829089">Free Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d5208e1665 class=n-a></a>Anstee QM, Targher G, Day CP: Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. <i>Nat Rev Gastroenterol Hepatol.</i> 2013; <b>10</b>(6): 330–44. <a target=xrefwindow id=d5208e1673 href="http://www.ncbi.nlm.nih.gov/pubmed/23507799">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1676 href="http://dx.doi.org/10.1038/nrgastro.2013.41">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d5208e1685 class=n-a></a>Anstee QM, Day CP: The genetics of NAFLD. <i>Nat Rev Gastroenterol Hepatol.</i> 2013; <b>10</b>(11): 645–55. <a target=xrefwindow id=d5208e1693 href="http://www.ncbi.nlm.nih.gov/pubmed/24061205">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1696 href="http://dx.doi.org/10.1038/nrgastro.2013.182">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d5208e1705 class=n-a></a>Valenti L, Al-Serri A, Daly AK, <i> et al.</i>: Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Hepatology.</i> 2010; <b>51</b>(4): 1209–17. <a target=xrefwindow id=d5208e1716 href="http://www.ncbi.nlm.nih.gov/pubmed/20373368">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1719 href="http://dx.doi.org/10.1002/hep.23622">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718472247"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e1728 class=n-a></a>Liu YL, Reeves HL, Burt AD, <i> et al.</i>: <i>TM6SF2</i> rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nat Commun.</i> 2014; <b>5</b>: 4309. <a target=xrefwindow id=d5208e1742 href="http://www.ncbi.nlm.nih.gov/pubmed/24978903">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1746 href="http://dx.doi.org/10.1038/ncomms5309">Publisher Full Text </a> | <a target=xrefwindow id=d5208e1749 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4279183">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718472247">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d5208e1762 class=n-a></a>Adams LA, Lymp JF, St Sauver J, <i> et al.</i>: The natural history of nonalcoholic fatty liver disease: a population-based cohort study. <i>Gastroenterology.</i> 2005; <b>129</b>(1): 113–21. <a target=xrefwindow id=d5208e1773 href="http://www.ncbi.nlm.nih.gov/pubmed/16012941">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1776 href="http://dx.doi.org/10.1053/j.gastro.2005.04.014">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d5208e1785 class=n-a></a>Wong VW, Wong GL, Choi PC, <i> et al.</i>: Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. <i>Gut.</i> 2010; <b>59</b>(7): 969–74. <a target=xrefwindow id=d5208e1796 href="http://www.ncbi.nlm.nih.gov/pubmed/20581244">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1799 href="http://dx.doi.org/10.1136/gut.2009.205088">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d5208e1809 class=n-a></a>Pais R, Charlotte F, Fedchuk L, <i> et al.</i>: A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. <i>J Hepatol.</i> 2013; <b>59</b>(3): 550–6. <a target=xrefwindow id=d5208e1820 href="http://www.ncbi.nlm.nih.gov/pubmed/23665288">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1823 href="http://dx.doi.org/10.1016/j.jhep.2013.04.027">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725264604"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e1832 class=n-a></a>McPherson S, Hardy T, Henderson E, <i> et al.</i>: Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. <i>J Hepatol. </i> 2015; <b>62</b>(5): 1148–55. <a target=xrefwindow id=d5208e1843 href="http://www.ncbi.nlm.nih.gov/pubmed/25477264">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1846 href="http://dx.doi.org/10.1016/j.jhep.2014.11.034">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725264604">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d5208e1859 class=n-a></a>Kleiner DE, Brunt EM, Van Natta M, <i> et al.</i>: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. <i>Hepatology.</i> 2005; <b>41</b>(6): 1313–21. <a target=xrefwindow id=d5208e1870 href="http://www.ncbi.nlm.nih.gov/pubmed/15915461">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1873 href="http://dx.doi.org/10.1002/hep.20701">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d5208e1882 class=n-a></a>Brunt EM, Kleiner DE, Wilson LA, <i> et al.</i>: Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. <i>Hepatology.</i> 2011; <b>53</b>(3): 810–20. <a target=xrefwindow id=d5208e1893 href="http://www.ncbi.nlm.nih.gov/pubmed/21319198">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1896 href="http://dx.doi.org/10.1002/hep.24127">Publisher Full Text </a> | <a target=xrefwindow id=d5208e1900 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3079483">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d5208e1909 class=n-a></a>Brunt EM, Kleiner DE, Behling C, <i> et al.</i>: Misuse of scoring systems. <i>Hepatology.</i> 2011; <b>54</b>(1): 369–70, author reply 370-1. <a target=xrefwindow id=d5208e1920 href="http://www.ncbi.nlm.nih.gov/pubmed/21488072">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1923 href="http://dx.doi.org/10.1002/hep.24347">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d5208e1932 class=n-a></a>Castera L, Pinzani M: Non-invasive assessment of liver fibrosis: are we ready? <i>Lancet.</i> 2010; <b>375</b>(9724): 1419–20. <a target=xrefwindow id=d5208e1940 href="http://www.ncbi.nlm.nih.gov/pubmed/20417845">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1943 href="http://dx.doi.org/10.1016/S0140-6736(09)62195-4">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d5208e1953 class=n-a></a>Castera L: Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. <i>Semin Liver Dis.</i> 2015; <b>35</b>(3): 291–303. <a target=xrefwindow id=d5208e1961 href="http://www.ncbi.nlm.nih.gov/pubmed/26378645">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1964 href="http://dx.doi.org/10.1055/s-0035-1562948">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726407940"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e1973 class=n-a></a>Friedrich-Rust M, Poynard T, Castera L: Critical comparison of elastography methods to assess chronic liver disease. <i>Nat Rev Gastroenterol Hepatol.</i> 2016; <b>13</b>(7): 402–11. <a target=xrefwindow id=d5208e1981 href="http://www.ncbi.nlm.nih.gov/pubmed/27273167">PubMed Abstract </a> | <a target=xrefwindow id=d5208e1984 href="http://dx.doi.org/10.1038/nrgastro.2016.86">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726407940">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727690188"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e1997 class=n-a></a>Xiao G, Zhu S, Xiao X, <i> et al.</i>: Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. <i>Hepatology.</i> 2017; <b>66</b>(5): 1486–501. <a target=xrefwindow id=d5208e2008 href="http://www.ncbi.nlm.nih.gov/pubmed/28586172">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2011 href="http://dx.doi.org/10.1002/hep.29302">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727690188">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726337641"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e2024 class=n-a></a>Boursier J, Vergniol J, Guillet A, <i> et al.</i>: Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. <i>J Hepatol.</i> 2016; <b>65</b>(3): 570–8. <a target=xrefwindow id=d5208e2035 href="http://www.ncbi.nlm.nih.gov/pubmed/27151181">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2038 href="http://dx.doi.org/10.1016/j.jhep.2016.04.023">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726337641">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718040351"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e2051 class=n-a></a>Angulo P, Bugianesi E, Bjornsson ES, <i> et al.</i>: Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. <i>Gastroenterology.</i> 2013; <b>145</b>(4): 782–9.e4. <a target=xrefwindow id=d5208e2062 href="http://www.ncbi.nlm.nih.gov/pubmed/23860502">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2065 href="http://dx.doi.org/10.1053/j.gastro.2013.06.057">Publisher Full Text </a> | <a target=xrefwindow id=d5208e2069 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3931256">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718040351">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726842812"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e2082 class=n-a></a>Oh H, Jun DW, Saeed WK, <i> et al.</i>: Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment. <i>Clin Mol Hepatol.</i> 2016; <b>22</b>(3): 327–35. <a target=xrefwindow id=d5208e2093 href="http://www.ncbi.nlm.nih.gov/pubmed/27729634">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2096 href="http://dx.doi.org/10.3350/cmh.2016.0049">Publisher Full Text </a> | <a target=xrefwindow id=d5208e2100 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5066376">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726842812">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d5208e2114 class=n-a></a>Kwok R, Tse YK, Wong GL, <i> et al.</i>: Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. <i>Aliment Pharmacol Ther.</i> 2014; <b>39</b>(3): 254–69. <a target=xrefwindow id=d5208e2125 href="http://www.ncbi.nlm.nih.gov/pubmed/24308774">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2128 href="http://dx.doi.org/10.1111/apt.12569">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727160500"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e2137 class=n-a></a>Karlas T, Petroff D, Sasso M, <i> et al.</i>: Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. <i>J Hepatol.</i> 2017; <b>66</b>(5): 1022–30. <a target=xrefwindow id=d5208e2148 href="http://www.ncbi.nlm.nih.gov/pubmed/28039099">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2151 href="http://dx.doi.org/10.1016/j.jhep.2016.12.022">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727160500">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726125121"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e2164 class=n-a></a>Kinner S, Reeder SB, Yokoo T: Quantitative Imaging Biomarkers of NAFLD. <i>Dig Dis Sci.</i> 2016; <b>61</b>(5): 1337–47. <a target=xrefwindow id=d5208e2172 href="http://www.ncbi.nlm.nih.gov/pubmed/26848588">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2175 href="http://dx.doi.org/10.1007/s10620-016-4037-1">Publisher Full Text </a> | <a target=xrefwindow id=d5208e2178 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4854639">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726125121">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718003865"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e2191 class=n-a></a>Wong VW, Chan RS, Wong GL, <i> et al.</i>: Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. <i>J Hepatol.</i> 2013; <b>59</b>(3): 536–42. <a target=xrefwindow id=d5208e2202 href="http://www.ncbi.nlm.nih.gov/pubmed/23623998">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2205 href="http://dx.doi.org/10.1016/j.jhep.2013.04.013">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718003865">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d5208e2218 class=n-a></a>Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, <i> et al.</i>: Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. <i>Gastroenterology.</i> 2015; <b>149</b>(2): 367–78.e5; quiz e14-5. <a target=xrefwindow id=d5208e2229 href="http://www.ncbi.nlm.nih.gov/pubmed/25865049">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2232 href="http://dx.doi.org/10.1053/j.gastro.2015.04.005">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d5208e2241 class=n-a></a>Stewart KE, Haller DL, Sargeant C, <i> et al.</i>: Readiness for behaviour change in non-alcoholic fatty liver disease: implications for multidisciplinary care models. <i>Liver Int.</i> 2015; <b>35</b>(3): 936–43. <a target=xrefwindow id=d5208e2252 href="http://www.ncbi.nlm.nih.gov/pubmed/24521540">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2255 href="http://dx.doi.org/10.1111/liv.12483">Publisher Full Text </a> | <a target=xrefwindow id=d5208e2259 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4266620">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/3421959"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e2269 class=n-a></a>Sanyal AJ, Chalasani N, Kowdley KV, <i> et al.</i>: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. <i>N Engl J Med.</i> 2010; <b>362</b>(18): 1675–85. <a target=xrefwindow id=d5208e2280 href="http://www.ncbi.nlm.nih.gov/pubmed/20427778">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2283 href="http://dx.doi.org/10.1056/NEJMoa0907929">Publisher Full Text </a> | <a target=xrefwindow id=d5208e2287 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2928471">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/3421959">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d5208e2300 class=n-a></a>Kowdley KV, <i> et al.</i>: Efficacy and safety of vitamin E in nonalcoholic steatohepatitis patients with and without diabetes: pooled analysis from the PIVENS and FLINT NIDDK NASH CRN trials. <i>Hepatology.</i> 2015; <b>62</b>: 264A.</span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d5208e2318 class=n-a></a>Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, <i> et al.</i>: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. <i>Hepatology.</i> 2003; <b>38</b>(4): 1008–17. <a target=xrefwindow id=d5208e2329 href="http://www.ncbi.nlm.nih.gov/pubmed/14512888">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2332 href="http://dx.doi.org/10.1053/jhep.2003.50420">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726042651"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e2341 class=n-a></a>Blais P, Lin M, Kramer JR, <i> et al.</i>: Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia. <i>Dig Dis Sci.</i> 2016; <b>61</b>(6): 1714–20. <a target=xrefwindow id=d5208e2352 href="http://www.ncbi.nlm.nih.gov/pubmed/26707137">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2355 href="http://dx.doi.org/10.1007/s10620-015-4000-6">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726042651">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d5208e2368 class=n-a></a>Kargiotis K, Athyros VG, Giouleme O, <i> et al.</i>: Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. <i>World J Gastroenterol.</i> 2015; <b>21</b>(25): 7860–8. <a target=xrefwindow id=d5208e2379 href="http://www.ncbi.nlm.nih.gov/pubmed/26167086">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2382 href="http://dx.doi.org/10.3748/wjg.v21.i25.7860">Publisher Full Text </a> | <a target=xrefwindow id=d5208e2386 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4491973">Free Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d5208e2395 class=n-a></a>Dobrzyn P, Dobrzyn A, Miyazaki M, <i> et al.</i>: Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. <i>Proc Natl Acad Sci U S A.</i> 2004; <b>101</b>(17): 6409–14. <a target=xrefwindow id=d5208e2406 href="http://www.ncbi.nlm.nih.gov/pubmed/15096593">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2409 href="http://dx.doi.org/10.1073/pnas.0401627101">Publisher Full Text </a> | <a target=xrefwindow id=d5208e2413 href="http://www.ncbi.nlm.nih.gov/pmc/articles/404058">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d5208e2423 class=n-a></a>Safadi R, Konikoff FM, Mahamid M, <i> et al.</i>: The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. <i>Clin Gastroenterol Hepatol.</i> 2014; <b>12</b>(12): 2085–91.e1. <a target=xrefwindow id=d5208e2434 href="http://www.ncbi.nlm.nih.gov/pubmed/24815326">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2437 href="http://dx.doi.org/10.1016/j.cgh.2014.04.038">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d5208e2446 class=n-a></a>Puri P, Daita K, Joyce A, <i> et al.</i>: The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. <i>Hepatology.</i> 2017. <a target=xrefwindow id=d5208e2454 href="http://www.ncbi.nlm.nih.gov/pubmed/28696585">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2457 href="http://dx.doi.org/10.1002/hep.29359">Publisher Full Text </a> | <a target=xrefwindow id=d5208e2460 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5764808">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/724234031"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e2469 class=n-a></a>Cipriani S, Mencarelli A, Palladino G, <i> et al.</i>: FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. <i>J Lipid Res.</i> 2010; <b>51</b>(4): 771–84. <a target=xrefwindow id=d5208e2480 href="http://www.ncbi.nlm.nih.gov/pubmed/19783811">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2483 href="http://dx.doi.org/10.1194/jlr.M001602">Publisher Full Text </a> | <a target=xrefwindow id=d5208e2487 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2842143">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/724234031">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d5208e2500 class=n-a></a>Haczeyni F, <i> et al.</i>: PPAR-δ agonist MBX-8025 abolishes lipotoxicity and reverses NASH in diabetic obese mice. <i>Hepatology.</i> 2016; <b>64</b>: 129A. </span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d5208e2518 class=n-a></a>Cariou B, Hanf R, Lambert-Porcheron S, <i> et al.</i>: Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. <i>Diabetes Care.</i> 2013; <b>36</b>(10): 2923–30. <a target=xrefwindow id=d5208e2529 href="http://www.ncbi.nlm.nih.gov/pubmed/23715754">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2532 href="http://dx.doi.org/10.2337/dc12-2012">Publisher Full Text </a> | <a target=xrefwindow id=d5208e2536 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3781493">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/722676659"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e2545 class=n-a></a>Boettcher E, Csako G, Pucino F, <i> et al.</i>: Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. <i>Aliment Pharmacol Ther.</i> 2012; <b>35</b>(1): 66–75. <a target=xrefwindow id=d5208e2556 href="http://www.ncbi.nlm.nih.gov/pubmed/22050199">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2559 href="http://dx.doi.org/10.1111/j.1365-2036.2011.04912.x">Publisher Full Text </a> | <a target=xrefwindow id=d5208e2563 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3488596">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/722676659">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d5208e2577 class=n-a></a>Jain MR, Giri SR, Trivedi C, <i> et al.</i>: Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. <i>Pharmacol Res Perspect.</i> 2015; <b>3</b>(3): e00136. <a target=xrefwindow id=d5208e2588 href="http://www.ncbi.nlm.nih.gov/pubmed/26171220">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2591 href="http://dx.doi.org/10.1002/prp2.136">Publisher Full Text </a> | <a target=xrefwindow id=d5208e2595 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4492752">Free Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d5208e2604 class=n-a></a>Saboo B, <i> et al.</i>: To Assess the Effect of 4 mg Saroglitazar on patients of diabetes dyslipidemia with nonalcoholic fatty liver disease. <i>Diabetes.</i> 2015; <b>64</b>: A180-A. </span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d5208e2622 class=n-a></a>Angelico F, Burattin M, Alessandri C, <i> et al.</i>: Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. <i>Cochrane Database Syst Rev.</i> 2007; (1): CD005166. <a target=xrefwindow id=d5208e2630 href="http://www.ncbi.nlm.nih.gov/pubmed/17253544">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2633 href="http://dx.doi.org/10.1002/14651858.CD005166.pub2">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725963353"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e2642 class=n-a></a>Armstrong MJ, Gaunt P, Aithal GP, <i> et al.</i>: Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. <i>Lancet.</i> 2016; <b>387</b>(10019): 679–90. <a target=xrefwindow id=d5208e2653 href="http://www.ncbi.nlm.nih.gov/pubmed/26608256">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2656 href="http://dx.doi.org/10.1016/S0140-6736(15)00803-X">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725963353">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d5208e2669 class=n-a></a>Ohki T, <i> et al.</i>: SGLT-2 inhibitors improved liver inflammation and fibrosis of NAFLD patients with type 2 diabetes mellitus with a favorable effect of weight reduction. <i>Hepatology.</i> 2016; <b>64</b>: 582A. </span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d5208e2687 class=n-a></a>Friedman SL, Ratziu V, Harrison SA, <i> et al.</i>: A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology.</i> 2018; <b>67</b>(5): 1754–67. <a target=xrefwindow id=d5208e2698 href="http://www.ncbi.nlm.nih.gov/pubmed/28833331">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2701 href="http://dx.doi.org/10.1002/hep.29477">Publisher Full Text </a> | <a target=xrefwindow id=d5208e2705 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5947654">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d5208e2715 class=n-a></a>Shiffman M, Freilich B, Vuppalanchi R, <i> et al.</i>: LP37: A Placebo-controlled, multicenter, double-blind, randomised trial of emricasan in subjects with non-alcoholic fatty liver disease (Nafld) and raised transaminases. <i>J Hepatol.</i> 2015; <b>62</b>(Supplement 2): S282-S. <a target=xrefwindow id=d5208e2726 href="http://dx.doi.org/10.1016/S0168-8278(15)30191-4">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d5208e2735 class=n-a></a>Budas G, Karnik S, Jonnson T, <i> et al.</i>: Reduction of liver steatosis and fibrosis with an ask1 inhibitor in a murine model of NASH is accompanied by improvements in cholesterol, bile acid and lipid metabolism. <i>J Hepatol.</i> 2016; <b>64</b>(2): S170. <a target=xrefwindow id=d5208e2746 href="http://dx.doi.org/10.1016/S0168-8278(16)01686-X">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d5208e2755 class=n-a></a>Loomba R, Lawitz E, Mantry PS, <i> et al.</i>: GS-4997, an Inhibitor of Apoptosis Signal-Regulating Kinase (ASK1), Alone or in Combination with Simtuzumab for the Treatment of Nonalcoholic Steatohepatitis (NASH): A Randomized, Phase 2 Trial. 2016; <b>64</b>(6): 1119A. <a target=xrefwindow id=d5208e2763 href="https://scholars.duke.edu/display/pub1241484">Reference Source</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d5208e2772 class=n-a></a>Reilly SM, Chiang SH, Decker SJ, <i> et al.</i>: An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice. <i>Nat Med.</i> 2013; <b>19</b>(3): 313–21. <a target=xrefwindow id=d5208e2783 href="http://www.ncbi.nlm.nih.gov/pubmed/23396211">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2786 href="http://dx.doi.org/10.1038/nm.3082">Publisher Full Text </a> | <a target=xrefwindow id=d5208e2790 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3594079">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d5208e2799 class=n-a></a>Mizrahi M, Shabat Y, Ben Ya'acov A, <i> et al.</i>: Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH. <i>J Inflamm Res.</i> 2012; <b>5</b>: 141–50. <a target=xrefwindow id=d5208e2810 href="http://www.ncbi.nlm.nih.gov/pubmed/23293533">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2813 href="http://dx.doi.org/10.2147/JIR.S35227">Publisher Full Text </a> | <a target=xrefwindow id=d5208e2817 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3534391">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d5208e2826 class=n-a></a>Fernandes P, <i> et al.</i>: Mechanism of anti-NASH effects of Solithromycin in a predictive NASH HCC mouse model. <i>Hepatology.</i> 2015; <b>62</b>: 1301A-A. </span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725357120"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d5208e2845 class=n-a></a>Harrison SA, Fecht W, Brunt EM, <i> et al.</i>: Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. <i>Hepatology.</i> 2009; <b>49</b>(1): 80–6. <a target=xrefwindow id=d5208e2856 href="http://www.ncbi.nlm.nih.gov/pubmed/19053049">PubMed Abstract </a> | <a target=xrefwindow id=d5208e2859 href="http://dx.doi.org/10.1002/hep.22575">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725357120">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 11 Jun 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-720.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-720.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> The Division of Internal Medicine, Virginia Commonwealth University, Richmond, USA<br/> <sup>2</sup> The Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, USA<br/> <p> <div class=margin-bottom> Somaya Albhaisi <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Arun Sanyal <br/> <span>Roles: </span> Conceptualization, Methodology, Resources, Supervision, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-720/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 11 Jun 2018, 7:720 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.14421.1">https://doi.org/10.12688/f1000research.14421.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2018 Albhaisi S and Sanyal A. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=15697 data-id=14421 data-downloads="" data-views="" data-scholar="10.12688/f1000research.14421.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-720/v1/pdf?article_uuid=672f1458-2272-408a-a8f3-951aed5ac6fd" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.14421.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Albhaisi S and Sanyal A. Recent advances in understanding and managing non-alcoholic fatty liver disease [version 1; peer review: 2 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):720 (<a href="https://doi.org/10.12688/f1000research.14421.1" target=_blank>https://doi.org/10.12688/f1000research.14421.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=14421 id=mobile-track-article-signin-14421 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/14421?target=/articles/7-720.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=15697 /> <input name=articleId type=hidden value=14421 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Valerio Nobili</strong>, Pediatric Department, University “La Sapienza”, Italy; Hepatology Gastroenterology and Nutrition, Bambino Gesù Hospital, Italy </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Claudia P de Oliveira</strong>, Faculdade de Medicina, Universidade de São Paulo, Brazil </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 11 Jun 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-720.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-720.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=35210-34745></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=35211-34746></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-720/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>11 Jun 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Valerio Nobili</strong>, Pediatric Department, University “La Sapienza”, Italy; Hepatology Gastroenterology and Nutrition, Bambino Gesù Hospital, Italy </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Claudia P de Oliveira</strong>, Faculdade de Medicina, Universidade de São Paulo, Brazil </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-720.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-720/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in understanding and managing...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-720/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-720/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-720/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Albhaisi S and Sanyal A');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-720/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-720",
            templates : {
                twitter : "Recent advances in understanding and managing non-alcoholic fatty.... Albhaisi S and Sanyal A, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-720/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in understanding and managing non-alcoholic fatty liver disease", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in understanding and managing non-alcoholic fatty liver disease", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/14421/15697")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "15697");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "34745": 0,
                           "34746": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "dc376b4c-e13f-4e4c-9aa5-1c78ffa0e35d";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-720.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-720.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-720.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-720.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-720.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>